Inovio developing vaccines to target coronavirus variants

 U.S. drug developer Inovio Pharmaceuticals Inc said on Monday it was developing next-generation COVID-19 vaccine candidates that could be tailored to the known and potentially the unknown SARS-CoV-2 variants.

Inovio began developing a COVID-19 vaccine last year, but is running behind rivals who have already introduced vaccines in the United States. A late-stage U.S. study of Inovio’s vaccine candidate is expected to start in the second quarter of 2021.

https://www.reuters.com/article/us-health-coronavirus-inovio-pharma/inovio-developing-vaccines-to-target-coronavirus-variants-idUSKCN2AT3ND